These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 23159084)
21. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases]. Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682 [TBL] [Abstract][Full Text] [Related]
22. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934 [TBL] [Abstract][Full Text] [Related]
23. [Successful chemotherapy of cancer. Remission of Hodgkin's disease. IV]. Lopez M Clin Ter; 2001; 152(3):203-6. PubMed ID: 11692542 [No Abstract] [Full Text] [Related]
24. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Santoro A; Viviani S; Villarreal CJ; Bonfante V; Delfino A; Valagussa P; Bonadonna G Cancer Treat Rep; 1986 Mar; 70(3):343-8. PubMed ID: 2420444 [TBL] [Abstract][Full Text] [Related]
25. [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma]. Zhen ZJ; Sun XF; Xia Y; Wang ZH; Ling JY Ai Zheng; 2006 Apr; 25(4):471-5. PubMed ID: 16613683 [TBL] [Abstract][Full Text] [Related]
27. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages? Andrieu JM; Colonna P J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234 [No Abstract] [Full Text] [Related]
28. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536 [TBL] [Abstract][Full Text] [Related]
29. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107 [TBL] [Abstract][Full Text] [Related]
30. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Federico M; Luminari S; Iannitto E; Polimeno G; Marcheselli L; Montanini A; La Sala A; Merli F; Stelitano C; Pozzi S; Scalone R; Di Renzo N; Musto P; Baldini L; Cervetti G; Angrilli F; Mazza P; Brugiatelli M; Gobbi PG; J Clin Oncol; 2009 Feb; 27(5):805-11. PubMed ID: 19124807 [TBL] [Abstract][Full Text] [Related]
32. Hodgkin's disease in children: correlation of clinical characteristics, staging procedures, and treatment at the University of Minnesota. McClain KL; Heise R; Day DL; Lee CK; Woods WG; Aeppli D Am J Pediatr Hematol Oncol; 1990; 12(2):147-54. PubMed ID: 1696073 [TBL] [Abstract][Full Text] [Related]
33. Treatment of pediatric Hodgkin disease avoiding radiotherapy: excellent outcome with the Rotterdam-HD-84-protocol. Hakvoort-Cammel FG; Buitendijk S; van den Heuvel-Eibrink M; Hählen K Pediatr Blood Cancer; 2004 Jul; 43(1):8-16. PubMed ID: 15170884 [TBL] [Abstract][Full Text] [Related]
34. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study. Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131 [TBL] [Abstract][Full Text] [Related]
35. [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil]. Qin Y; Shi YK; He XH; Yang JL; Yang S; Yu YX; Li B; Wang QL; Zhou LQ; Sun Y Ai Zheng; 2006 Apr; 25(4):481-5. PubMed ID: 16613685 [TBL] [Abstract][Full Text] [Related]
36. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages? Diehl V; Fuchs M; Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996 [TBL] [Abstract][Full Text] [Related]
38. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805 [TBL] [Abstract][Full Text] [Related]
39. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades. Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262 [TBL] [Abstract][Full Text] [Related]
40. ABVD, the Stanford V regimen, and BEACOPP for Hodgkin's lymphoma: what should an oncologist do? Connors JM Clin Lymphoma; 2005 Jun; 6(1):50-1. PubMed ID: 15989708 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]